New Pancreatic Cancer Pill Shrinks Tumors in Major Trial
A pill that could double survival for one of the deadliest cancers.
A new pill called daraxonrasib is being hailed as a major breakthrough for pancreatic cancer, one of the deadliest cancers. In a trial of 61 patients with advanced pancreatic cancer that had spread, the drug shrank tumors or made them disappear in over 60% of patients. In about 8% of patients, the cancer became undetectable on scans. After one year, 76.6% of patients were still alive, compared to 40-45% with chemotherapy alone. Doctors are calling this the closest to a cure they've seen for this disease.
Pancreatic cancer is particularly deadly: half of people diagnosed die within three months, and only about 3% survive five years once it spreads. The new drug works by targeting specific genetic mutations that drive tumor growth. These mutations are found in most pancreatic cancers and also in dozens of other cancers, raising hopes that the treatment could help many more people. The trial followed patients for an average of 18 months, and some have not seen the cancer return.
However, doctors caution that the pill is not yet a cure. They don't know how long it can keep the cancer at bay, and longer studies are needed. The results were presented at a medical conference and have not yet been published in a peer-reviewed journal. More trials are required before the treatment can be approved for widespread use. Still, for a cancer with such low survival rates, this offers real hope and could eventually lead to treatments for other cancers with similar mutations.
- In a trial, the pill daraxonrasib made cancer undetectable in 1 in 12 patients with advanced pancreatic cancer.
- After one year, 76.6% of patients taking the pill were alive, compared to 40-45% with chemotherapy alone.
- The drug targets mutations found in most pancreatic cancers and could potentially treat other cancers too.
Why It Matters
This could significantly extend lives for people with one of the deadliest cancers, offering hope where there was little.